10:50 AM EDT, 08/04/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

After Q2 results, we cut our target to $12 from $14, 10.3x our 2026 EPS, a sharp discount to AVTR's five-year historical forward P/E average of 21.0x, justified by the challenging environment the company is operating in. We lower our 2025 EPS estimate to $0.96 from $1.02. We maintain our 2026 EPS view at $1.16. We think Avantor's ( AVTR ) Q2 results and guidance reflect ongoing uncertainties in the operating environment due to funding and policy-related headwinds, which we expect to continue in the near-term. Q2 net sales declined by 1.1% Y/Y and were marked by divergent trends across the two main segments, with the core Laboratory Solutions revenue down 3% Y/Y, indicating ongoing headwinds in this core business. In contrast, the Bioscience Production segment demonstrated resilience with better-than-anticipated 2.6% Y/Y growth. Yet, we remain underwhelmed by the reduced organic revenue guidance of -2% to 0% versus -1% to +1% earlier, and forecast a 1.8% Y/Y decline in top-line revenue this year.